Overwhelming Bipartisan Support for Access to FDA-Approved Alzheimer's Treatments on Display in Health Subcommittee Hearing
WASHINGTON, April 26, 2023 /PRNewswire/ -- Today, the Alzheimer's Association brought its purple presence again to Capitol Hill, urging access to FDA-approved Alzheimer's treatments during Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure's testimony before the House Committee on Energy and Commerce's Health Subcommittee. Adding to the bipartisan momentum from last month's budget hearings in the House and Senate, members of Congress from both sides of the aisle urged Administrator Brooks-LaSure to reverse CMS's unprecedented decision blocking access to Food and Drug Administration (FDA)-approved Alzheimer's treatments.
- "She also failed to explain why CMS has imposed an inconsistent, stricter standard for this class of treatments.
- CMS must reverse course and ensure full access to FDA-approved Alzheimer's treatments."
- "Thank you to subcommittee members on both sides of the aisle for reaffirming the bipartisan support for access to FDA-approved Alzheimer's treatments," said Egge.
- recognized the Alzheimer's Association presence in the hearing room and reiterated the bipartisan support in the fight against Alzheimer's and other dementia.